Orphanet Journal of Rare Diseases | Impact of Lysosomal Storage Diseases on Quality of Life and Economic Burden

Recommend:

This study is the first comprehensive assessment of the economic burden and quality of life impact of Lysosomal Storage Disorders (LSDs) on Spanish patients and their families, providing crucial evidence for disease management and policy development.

 

Literature Overview
This article, titled 'Human, economic, and social impact of lysosomal storage diseases', was published in the Orphanet Journal of Rare Diseases. It reviews and summarizes the economic and social burdens of LSDs on patients, families, and the healthcare system. The analysis of survey data from 86 Spanish patients reveals the profound impact of the disease on quality of life, healthcare resource utilization, and household income. The study also highlights the mental health impact on both patients and caregivers, and the high proportion of out-of-pocket expenses, reflecting the inadequacy of the healthcare system.

Background Information
Lysosomal Storage Disorders (LSDs) are a group of inherited metabolic diseases caused by deficiencies in lysosomal enzymes, leading to the accumulation of macromolecules within lysosomes and resulting in multi-system dysfunction. These diseases are collectively rare but individually heterogeneous, with clinical manifestations including neurodevelopmental impairments, organ enlargement, and skeletal deformities. Current treatment options are limited, including enzyme replacement therapy, gene therapy, and small molecule drugs, but full reversal of disease progression remains unachievable. While some studies have explored the clinical and genetic characteristics of LSDs, a systematic evaluation of their economic and social burden, particularly on household and national healthcare expenditures, is still lacking. This study fills that gap by quantifying the annual healthcare costs, informal care costs, and quality of life deterioration among Spanish LSD patients using questionnaires and expert interviews.

 

A tool to assess the pathogenic potential of gene variants, providing a reference for functional analysis.

Learn More

 

Research Methods and Procedures
This cross-sectional study was conducted in five stages: 1) Literature review, 2) Focus groups with patients and healthcare professionals, 3) Questionnaire design, 4) Survey of patients and caregivers, and 5) Cost analysis. The questionnaire collected data on sociodemographic characteristics, clinical variables, quality of life, and medical and non-medical expenditures. Statistical analysis was performed using STATA v14 to ensure data accuracy and consistency. A total of 86 patients were included in the study, with 22 completing the questionnaire themselves and 64 filled out by caregivers, covering 12 LSD subtypes.

Key Findings and Insights

• Average patients require 107.8 annual medical visits, with a high proportion of out-of-pocket costs for physical therapy, speech therapy, and psychotherapy (64.2%, 44.6%, and 77.5%, respectively).
• The average annual total cost per patient was €228,232.60, with 81.4% covered by the Spanish Health System (SHS), and 15.9% representing indirect costs such as caregiver time and productivity loss.
• The average annual out-of-pocket expenditure for families was €6,170.20, primarily for formal care, uncovered treatments, and home modifications.
• Nearly 30% of patients experience severe functional or cognitive impairments, significantly affecting daily activities, emotional well-being, and social participation.
• Almost half of caregivers reported reduced working hours or job loss due to caregiving, increasing household financial stress.
• Both patients and caregivers frequently reported emotional distress, with high rates of anxiety and depression, underscoring the importance of psychological support.

Significance and Future Directions
This study provides comprehensive economic and social data for LSD management in Spain and across Europe, highlighting the need for integrated support systems to reduce disease burden. Future studies should adopt longitudinal designs and stratify by disease subtype and treatment status to more precisely assess the impact of therapies on non-medical and indirect costs. Policymakers are encouraged to expand healthcare coverage to include more non-pharmacological treatments, thereby alleviating financial strain on families.

 

Input a gene to explore its associated signaling pathways and known upstream/downstream molecules, suitable for studying gene regulation and functional networks.

Learn More

 

Conclusion
Lysosomal Storage Disorders (LSDs) impose significant economic and social burdens on patients and their families. The study shows that the average annual healthcare expenditure per patient exceeds €228,000, with most costs covered by the Spanish Health System, yet families still bear an average of €6,170 in out-of-pocket expenses, primarily for home care modifications and uncovered treatments. Patients' quality of life is significantly reduced, and caregivers face career interruptions and psychological stress due to long-term caregiving. These disorders not only affect individual health but also have profound implications for family and social structures. The study calls for stronger policy support, expanded healthcare coverage, and improved access to psychological and social services. Future research should further explore the cost-effectiveness of treatment interventions and develop tailored support strategies to improve the overall quality of life for patients and caregivers.

 

Eduardo Brignani, María José de Castro-López, Antonio Gonzalez-Meneses, Gabriel Fernando Ballester-Lozano, and Héctor David de Paz. Human, economic, and social impact of lysosomal storage diseases. Orphanet Journal of Rare Diseases.